Phenibut

Phenibut

SCHEMBL351501

NC[C@H](CC(=O)O)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GABBR2 O75899 6/20 1.00
GABBR1 Q9UBS5 6/20 1.00
LMNA P02545 2/20 0.70
CYP2C9 P11712 2/20 0.70
CYP2C19 P33261 2/20 0.70
MEN1 O00255 2/20 0.70
KMT2A Q03164 2/20 0.70
CYP3A4 P08684 1/20 0.70
ADORA3 P0DMS8 1/20 0.70
NFKB1 P19838 1/20 0.70
DRD3 P35462 1/20 0.70
BLM P54132 1/20 0.70
CYP1A2 P05177 1/20 0.70
CYP2D6 P10635 1/20 0.70
THRB P10828 1/20 0.70
TSHR P16473 1/20 0.70
MAPT P10636 1/20 0.53
GAA P10253 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenibut SCHEMBL9545047 1.00 GABBR2 (1.00) GABBR2GABBR1LMNACYP2C9CYP2C19
Phenibut SCHEMBL340838 1.00 GABBR2 (1.00) GABBR2GABBR1LMNACYP2C9CYP2C19
Phenibut SCHEMBL22831453 0.98 GABBR2 (0.96) GABBR2GABBR1LMNACYP2C9CYP2C19
Phenibut SCHEMBL3053795 0.98 GABBR2 (0.96) GABBR2GABBR1LMNACYP2C9CYP2C19
Phenibut SCHEMBL27912811 0.96 GABBR2 (0.92) GABBR2GABBR1LMNACYP2C9CYP2C19
Phenibut SCHEMBL28119792 0.94 GABBR2 (0.89) GABBR2GABBR1LMNACYP2C9CYP2C19
SCHEMBL503819 0.87 GABBR2 (0.76) GABBR2GABBR1LMNACYP2C9CYP2C19
SCHEMBL27691658 0.86 GABBR2 (0.75) GABBR2GABBR1LMNACYP2C9CYP2C19
Hydrochloric Acid SCHEMBL7092228 0.85 GABBR2 (0.73) GABBR2GABBR1LMNACYP2C9CYP2C19
SCHEMBL6734410 0.85 GABBR2 (0.73) GABBR2GABBR1LMNACYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120041848-A Method for electrochemically synthesizing chiral beta-ester nitrile and application of chiral beta-ester nitrile in synthesis of baclofen and rolipram 中国科学院化学研究所 2025-05-27 CN disclosed
CN-120041848-A Method for electrochemically synthesizing chiral beta-ester nitrile and application of chiral beta-ester nitrile in synthesis of baclofen and rolipram 中国科学院化学研究所 2025-05-27 CN disclosed
CN-119899141-A Chiral pentafluorophenyl urea compound and preparation method and application thereof 沈阳化工大学 2025-04-29 CN disclosed
CN-119899141-A Chiral pentafluorophenyl urea compound and preparation method and application thereof 沈阳化工大学 2025-04-29 CN disclosed
CN-116655482-B Preparation method of gamma-aminobutyric acid derivatives 贵州大学 2024-06-04 CN disclosed
CN-116655482-A Preparation method of gamma-aminobutyric acid derivatives 贵州大学 2023-08-29 CN disclosed
US-20210171442-A1 PROCESS FOR THE PREPARATION OF BACLOFEN AND ITS INTERMEDIATE PIRAMAL PHARMA LIMITED (IN) 2021-06-10 US disclosed
EP-3599246-A1 MEANS AND METHODS FOR SYNTHESIZING PRECURSORS OF Y-AMINOBUTYRIC ACID (GABA) ANALOGS RIJKSUNIVERSITEIT GRONINGEN (NL) 2020-01-29 EP disclosed
US-20180208544-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF BACLOFEN AND ITS INTERMEDIATE Piramal Enterprises Limited (IN) 2018-07-26 US disclosed
CN-104662015-B Complement pathway modulators and uses thereof 诺华股份有限公司 2017-03-29 CN disclosed
US-20170008863-A1 SYNTHESIS OF THERAPEUTIC AND DIAGNOSTIC DRUGS CENTERED ON REGIOSELECTIVE AND STEREOSELECTIVE RING OPENING OF AZIRIDINIUM IONS CHONG, HYUN-SOON, PHD 2017-01-12 US disclosed
US-9446995-B2 Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions ILLINOIS INSTITUTE OF TECHNOLOGY (US) 2016-09-20 US disclosed
CN-104662015-A Complement pathway modulators and uses thereof NOVARTIS AG 2015-05-27 CN disclosed
US-8791295-B2 Method of producing purified optically acitve 4-amino-3-(substituted phenyl)butanoic acid compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-07-29 US disclosed
US-8293926-B2 Method of producing optically active 4-amino-3-substituted phenylbutanoic acid SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-23 US disclosed
US-20120016021-A1 METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS XENOPORT, INC. (US) 2012-01-19 US disclosed
WO-2012009646-A1 METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS XENOPORT, INC. (US) 2012-01-19 WO disclosed
US-20110087049-A1 METHOD OF PRODUCING PURIFIED OPTICALLY ACITVE 4-AMINO-3-(SUBSTITUTED PHENYL)BUTANOIC ACID COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED 2011-04-14 US disclosed
US-20090137819-A1 Method of Producing Optically Active 4-Amino-3-Substituted Phenylbutanoic Acid SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180208544-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF BACLOFEN AND ITS INTERMEDIATE SLC6A13, SLC6A1, SLC6A11 GABBR2 5/4885GABBR1 6/4885LMNA 1512/4885
US-20090137819-A1 Method of Producing Optically Active 4-Amino-3-Substituted Phenylbutanoic Acid ALAD, ATP6V1B1, DAO GABBR2 36/4885GABBR1 77/4885LMNA 2454/4885
US-20210171442-A1 PROCESS FOR THE PREPARATION OF BACLOFEN AND ITS INTERMEDIATE SLC6A13, GRHPR, SLC6A1 GABBR2 5/4885GABBR1 6/4885LMNA 1516/4885
US-20170008863-A1 SYNTHESIS OF THERAPEUTIC AND DIAGNOSTIC DRUGS CENTERED ON REGIOSELECTIVE AND STEREOSELECTIVE RING OPENING OF AZIRIDINIUM IONS AZI2, ABL1, DHPS GABBR2 264/4885GABBR1 242/4885LMNA 4686/4885
US-20110087049-A1 METHOD OF PRODUCING PURIFIED OPTICALLY ACITVE 4-AMINO-3-(SUBSTITUTED PHENYL)BUTANOIC ACID COMPOUND ALAD, OR10J3, ACMSD GABBR2 44/4885GABBR1 41/4885LMNA 3798/4885
US-20120016021-A1 METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS GABBR2, GABBR1, GABRB1 GABBR2 1/4885GABBR1 2/4885LMNA 2604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.